Quarterly ResultMay 13, 2026, 08:57 AM
Onconetix Q1 Net Loss Narrows to $4.21M; Going Concern Doubt
AI Summary
Onconetix reported a net loss of $4.21 million for Q1 2026, an improvement from $8.55 million in Q1 2025, largely due to changes in fair value of derivative liabilities. However, revenue significantly decreased to $21,457 from $101,630 in the prior year. The company continues to incur substantial operating losses and has a cash balance of $3.7 million as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern. Management plans to pursue additional equity or debt financing to support operations and strategic initiatives.
Key Highlights
- Substantial doubt about Onconetix's ability to continue as a going concern.
- Net loss for Q1 2026 narrowed to $4.21 million from $8.55 million in Q1 2025.
- Revenue for Q1 2026 decreased to $21,457 from $101,630 in Q1 2025.
- Cash balance was $3.72 million as of March 31, 2026, down from $5.22 million at Dec 31, 2025.
- Cash used in operating activities was $2.12 million in Q1 2026.
- Goodwill impairment loss was $8.13 million in Q1 2026, compared to $10.92 million in Q1 2025.
- Total assets decreased to $14.83 million from $24.93 million at December 31, 2025.